Free Trial
OTCMKTS:ORINY

Orion OYJ Q1 2026 Earnings Results & Report

Orion OYJ logo
$57.89 0.00 (0.00%)
As of 11/12/2026 02:59 PM Eastern

Orion OYJ reported Q1 2026 earnings on April 23, 2026. The company reported EPS of $0.37, while revenue was $488.80 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Orion OYJ EPS Results

Actual EPS
$0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Orion OYJ Revenue Results

Actual Revenue
$488.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Orion OYJ Q1 2026 Earnings FAQ

Orion OYJ (OTCMKTS:ORINY) reported earnings of $0.37 per share for Q1 2026. The report was announced on Thursday, April 23, 2026.

Orion OYJ reported revenue of $488.80 million for Q1 2026.

Orion OYJ Earnings Headlines

Orion Oyj
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Orion OYJ Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orion OYJ? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orion OYJ and other key companies, straight to your email.

About Orion OYJ

Orion OYJ (OTCMKTS:ORINY) is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies.

Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.

Orion serves customers in Finland and other European markets, while partnerships and product sales extend its reach to markets around the world. Its operations also include research and development, manufacturing and the commercialization of medicines.

View Orion OYJ Profile